SEP Enhanced the Antitumor Activity of 5-fluorouracil by Up-regulating NKG2D/MICA and Reversed Immune Suppression Via Inhibiting ROS and Caspase-3 in Mice

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Jul 8

PMID 27385218

Citations 8

Authors

Mengyun Ke

Hui Wang

Yiran Zhou

Jingwen Li

Yang Liu

Min Zhang

Jie Dou

Tao Xi

Baiyong Shen

Changlin Zhou

Affiliations

Soon will be listed here.

Abstract

Chemotherapy and immunotherapy are the main remedies used in cancer treatment. Because immunotherapy can not only reduce the toxicity of chemotherapeutics but also enhance antitumor effects in vivo, combining these two therapies is a trend that continues to gain more attention in clinic. SEP, a polysaccharide isolated from Strongylocentrotus nudus egg, has been reported to display antitumor activity by stimulating immune cells, including NK and T cells, via TLR2 and TLR4. In the present study, the synergistic effect between SEP and 5-fluorouracil (5-FU), a traditional cytotoxic drug, in vitro and in vivo was investigated. The results obtained indicated that SEP alone stimulated NK-92 cytotoxicity and coordinated with 5-FU to augment the cytotoxicity of NK-92 cells against HepG-2 or A549 cells in vitro. SEP promoted NK-92 activity by stimulating NKG2D and its downstream DAP10/PI3K/Erk signaling pathway. Additionally, 5-FU could increase MICA expression on HepG-2 or A549 cells and prevent membrane MICA from shedding as soluble MICA, which were abrogated in the tumor cells transfected with ADAM 10 overexpression plasmid. Moreover, in H22- or Lewis lung cancer (LLC)-bearing mouse models, SEP reversed 5-FU-induced atrophy and apoptosis in both the spleen and bone marrow in vivo by suppressing ROS generation and caspase-3 activation. All of these results highlight the potential for the combination of SEP and 5-FU in cancer therapy in the future.

Citing Articles

Preparation Optimization and Immunological Activity Studies of L. Polysaccharides Liposomes.

Li Y, Jia G, Li T, Zhou X, Zhao H, Cao J Curr Pharm Des. 2024; 30(10):786-797.

PMID: 38385493 DOI: 10.2174/0113816128279071231204071210.

Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands.

Li G, Nikkhoi S, Hatefi A Med Oncol. 2023; 40(4):110.

PMID: 36862260 PMC: 10794068. DOI: 10.1007/s12032-023-01975-1.

Biomaterials and Bioactive Natural Products from Marine Invertebrates: From Basic Research to Innovative Applications.

Romano G, Almeida M, Coelho A, Cutignano A, Goncalves L, Hansen E Mar Drugs. 2022; 20(4).

PMID: 35447892 PMC: 9027906. DOI: 10.3390/md20040219.

Leveraging NKG2D Ligands in Immuno-Oncology.

Fuertes M, Domaica C, Zwirner N Front Immunol. 2021; 12:713158.

PMID: 34394116 PMC: 8358801. DOI: 10.3389/fimmu.2021.713158.

NKG2D Ligand Shedding in Response to Stress: Role of ADAM10.

Zingoni A, Vulpis E, Loconte L, Santoni A Front Immunol. 2020; 11:447.

PMID: 32269567 PMC: 7109295. DOI: 10.3389/fimmu.2020.00447.

References

Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N . Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol. 2008; 27(3):93-110. DOI: 10.1080/08830180801911743. View

Brandt C, Baratin M, Yi E, Kennedy J, Gao Z, Fox B . The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009; 206(7):1495-503. PMC: 2715080. DOI: 10.1084/jem.20090681. View

Bert N, Gasser S . Advances in NKG2D ligand recognition and responses by NK cells. Immunol Cell Biol. 2014; 92(3):230-6. DOI: 10.1038/icb.2013.111. View

Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T . Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer. 2003; 104(3):354-61. DOI: 10.1002/ijc.10966. View

Ke M, Wang H, Zhang M, Tian Y, Wang Y, Li B . The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo. Biochem Pharmacol. 2014; 89(1):119-30. DOI: 10.1016/j.bcp.2014.02.024. View

Wang M, Wang H, Tang Y, Kang D, Gao Y, Ke M . Effective inhibition of a Strongylocentrotus nudus eggs polysaccharide against hepatocellular carcinoma is mediated via immunoregulation in vivo. Immunol Lett. 2011; 141(1):74-82. DOI: 10.1016/j.imlet.2011.08.001. View

Numazawa S, Sugihara K, Miyake S, Tomiyama H, Hida A, Hatsuno M . Possible involvement of oxidative stress in 5-fluorouracil-mediated myelosuppression in mice. Basic Clin Pharmacol Toxicol. 2010; 108(1):40-5. DOI: 10.1111/j.1742-7843.2010.00621.x. View

Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K . Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res. 2009; 69(20):8050-7. DOI: 10.1158/0008-5472.CAN-09-0789. View

Friberg L, Karlsson M . Mechanistic models for myelosuppression. Invest New Drugs. 2003; 21(2):183-94. DOI: 10.1023/a:1023573429626. View

10.

Salih H, Rammensee H, Steinle A . Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002; 169(8):4098-102. DOI: 10.4049/jimmunol.169.8.4098. View

11.

Correale P, Cusi M, Tsang K, Del Vecchio M, Marsili S, La Placa M . Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon.... J Clin Oncol. 2005; 23(35):8950-8. DOI: 10.1200/JCO.2005.12.147. View

12.

Apetoh L, Ladoire S, Coukos G, Ghiringhelli F . Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. Ann Oncol. 2015; 26(9):1813-1823. DOI: 10.1093/annonc/mdv209. View

13.

Huo L, Yao H, Wang X, Wong G, Kung H, Lin M . Inhibition of melanoma growth by subcutaneous administration of hTERTC27 viral cocktail in C57BL/6 mice. PLoS One. 2010; 5(9):e12705. PMC: 2938346. DOI: 10.1371/journal.pone.0012705. View

14.

Wu J, Song Y, Bakker A, Bauer S, Spies T, Lanier L . An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999; 285(5428):730-2. DOI: 10.1126/science.285.5428.730. View

15.

Tassi I, Cella M, Gilfillan S, Turnbull I, Diacovo T, Penninger J . p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity. 2007; 27(2):214-27. DOI: 10.1016/j.immuni.2007.07.014. View

16.

Coudert J, Held W . The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol. 2006; 16(5):333-43. DOI: 10.1016/j.semcancer.2006.07.008. View

17.

Wang S, Zheng G, Tian S, Zhang Y, Shen L, Pak Y . Echinacoside improves hematopoietic function in 5-FU-induced myelosuppression mice. Life Sci. 2015; 123:86-92. DOI: 10.1016/j.lfs.2015.01.002. View

18.

Emens L, Middleton G . The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015; 3(5):436-43. PMC: 5012642. DOI: 10.1158/2326-6066.CIR-15-0064. View

19.

Luo Y, Yang X, Zhao S, Wei C, Yin Y, Liu T . Hydrogen sulfide prevents OGD/R-induced apoptosis via improving mitochondrial dysfunction and suppressing an ROS-mediated caspase-3 pathway in cortical neurons. Neurochem Int. 2013; 63(8):826-31. DOI: 10.1016/j.neuint.2013.06.004. View

20.

Lopez-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S . NKG2D signaling in cancer immunosurveillance. Int J Cancer. 2014; 136(8):1741-50. DOI: 10.1002/ijc.28775. View